Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →"Bristol is clearly not interested in putting all of its eggs in one basket" — the analysis frames the $1.2 billion CytomX deal as prudent diversification…
Deals mask CytomX's fundamental problem: in-house pipeline delivered little of value over 16 years, and 'until it does its shares will languish' — the masked…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS paid CytomX $50M upfront plus research funding and up to $298M per target in development, regulatory and commercial milestones across four oncology targets including CTLA-4. The deal validated CytomX's Probody masked-antibody platform and was later expanded to eight targets in 2017 (and again in 2021).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / CytomX Therapeutics, Inc. (this deal) | 2014 | $1.2B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2014 deals · Bristol-Myers Squibb Company deals · Oncology deals